Kintor Pharmaceutical closes RMB115m pre-IPO Series F round

The anti-cancer drug research and development company Kintor Pharmaceutical has completed a Series F round of financing, raising 115 million US dollars prior its IPO.
The investors were Gree Electric Appliances(lead investor), Highlight Capital, Cherry Cheeks and Foresight Fund.

The anti-cancer drug research and development company Kintor Pharmaceutical has completed a Series F round of financing, raising 115 million US dollars prior its IPO.

The investors were Gree Electric Appliances(lead investor), Highlight Capital, Cherry Cheeks and Foresight Fund.

Kintor Pharmaceutical is a company devoted to anti-cancer drugs. The company’s in-development products include a new generation of anti-prostate cancer drugs that inhibit androgen receptors and kinase-targeted inhibitors for the treatment of breast cancer, lung cancer and liver cancer.

Proxalutamide was approved by the FDA of the United States for clinical trials in August 2015.

According to incomplete statistics, there have been 33 financing events in its field of medical and health care.

本轮投资领投方格力电器成立于1985年3月,前身为特区工业发展总公司,2009年完成公司制改造,是目前全球最大的集研发、生产、销售、服务于一体的专业化空调企业。格力电器(领投),近期还投资过华大北斗、万里红等企业。

Gree Electric Appliances, thelead investor for this round, founded in March 1985, was formerly known as Special Zone Industrial Development Corporation. It has completed its corporate reform in 2009, and is currently the world’s largest professional air-conditioning enterprise integrating R&D, production, sales and service.

Gree has also recently led the investments in Allystar and Beijing Superred Technology.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/24/kintor-pharmaceutical-closes-rmb115m-pre-ipo-series-f-round/.

Leave a Reply

Please Login to Comment